Ivermectin Reproposing for Mild Stage COVID-19 Outpatients
Status:
Completed
Trial end date:
2021-01-18
Target enrollment:
Participant gender:
Summary
Background:
The emergency of COVID-19, along with the current difficulties in responding to the high
demand for vaccines, requests to the scientific community to find alternative treatments
based on reuse of drugs as a strategy to prevent the progression of the disease in patients
infected with SARS COV 2.
Objetive This study aims to evaluate the use of ivermectin in mild-stage patients to increase
outpatient discharge and prevent the progression to moderate or severe stages of the disease.
Added value of this study We found that an intervention with ivermectin has impacted on the
PPS in a population of outpatients care, between the 5th and 9th day. Also, the treatment
increased the probability to obtain outpatient discharge, even in the presence of
comorbidities.
Implications of all available evidence.
Research in Context According to the COVID-19 Treatment Guidelines by the NIH, most trials
have several limitations. It needs results from adequately powered and well-designed clinical
trials to provide evidence-based guidance on the role of ivermectin in the treatment of
COVID- 19. However, our study shows overlaps in benefits with other authors, and taking
together, these results are encouraging for further study about repurposing ivermectin for
the treatment of COVID-19.